Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : BRMRCKBDR003
Share Class Description:
BSP:MRCK34: Shs Unsponsored Brazilian Depository Receipt Repr 1 ShCompare
Compare
Traded in other countries / regions
MRK.USA0QAH.UKMRK.CanadaMRCK34.Brazil6MK.GermanyMRK.ArgentinaMRK.MexicoMRK.PeruMRK.AustriaMRK.Chile1MRKX.Italy6MK.BulgariaMRK.FranceMRK.Ukraine IPO Date
2011-12-28Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.27 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | 1.34 | |||||
| Interest Coverage | 15.92 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 3.93 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.6 | |||||
| 3-Year EBITDA Growth Rate | 12.8 | |||||
| 3-Year EPS without NRI Growth Rate | 8.3 | |||||
| 3-Year FCF Growth Rate | 23.2 | |||||
| 3-Year Book Growth Rate | 6.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.27 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.9 | |||||
| 9-Day RSI | 49.23 | |||||
| 14-Day RSI | 48.29 | |||||
| 3-1 Month Momentum % | -10.59 | |||||
| 6-1 Month Momentum % | -27 | |||||
| 12-1 Month Momentum % | -38.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | |||||
| Quick Ratio | 1.16 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 152.7 | |||||
| Days Sales Outstanding | 63.33 | |||||
| Days Payable | 89.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.97 | |||||
| Dividend Payout Ratio | 0.29 | |||||
| 3-Year Dividend Growth Rate | 5.7 | |||||
| Forward Dividend Yield % | 2.93 | |||||
| 5-Year Yield-on-Cost % | 4.07 | |||||
| Shareholder Yield % | 4.19 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.42 | |||||
| Operating Margin % | 31.91 | |||||
| Net Margin % | 27.27 | |||||
| EBITDA Margin % | 40.78 | |||||
| FCF Margin % | 26.2 | |||||
| ROE % | 39.07 | |||||
| ROA % | 15.34 | |||||
| ROIC % | 22.07 | |||||
| 3-Year ROIIC % | 179.56 | |||||
| ROC (Joel Greenblatt) % | 83.52 | |||||
| ROCE % | 24.72 | |||||
| Years of Profitability over Past 10-Year | 10 | |||||
| Moat score | 8 | |||||
| Tariff score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.91 | |||||
| Forward PE Ratio | 8.67 | |||||
| PE Ratio without NRI | 10.5 | |||||
| Shiller PE Ratio | 21.56 | |||||
| Price-to-Owner-Earnings | 15.46 | |||||
| PEG Ratio | 1.12 | |||||
| PS Ratio | 3.25 | |||||
| PB Ratio | 4.26 | |||||
| Price-to-Tangible-Book | 18.9 | |||||
| Price-to-Free-Cash-Flow | 12.2 | |||||
| Price-to-Operating-Cash-Flow | 9.95 | |||||
| EV-to-EBIT | 10.77 | |||||
| EV-to-Forward-EBIT | 8.56 | |||||
| EV-to-EBITDA | 8.87 | |||||
| EV-to-Forward-EBITDA | 7.9 | |||||
| EV-to-Revenue | 3.62 | |||||
| EV-to-Forward-Revenue | 3.56 | |||||
| EV-to-FCF | 13.56 | |||||
| Price-to-GF-Value | 0.65 | |||||
| Price-to-Projected-FCF | 1.23 | |||||
| Price-to-Median-PS-Value | 0.74 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.98 | |||||
| Price-to-Graham-Number | 2.97 | |||||
| Earnings Yield (Greenblatt) % | 9.29 | |||||
| FCF Yield % | 8.29 | |||||
| Forward Rate of Return (Yacktman) % | 16.07 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers